Claims

1. Use of an agent comprising magnesium orotate and folic acid or folates or tautomers and salts thereof in the manufacture of a medicament for the prophylaxis and treatment of dementia.

2. The use according to claim 1 in the prophylaxis and treatment of dementia selected from Alzheimer's dementia or Alzheimer’s disease, dementia in Alzheimer’s disease with early onset (type 2), dementia in Alzheimer’s disease with late onset (type 1), dementia in Alzheimer’s disease, atypical or mixed type, vascular dementia, Lewy body dementia.

3. Use of an agent comprising magnesium orotate and folic acid or folates or tautomers and salts thereof in the manufacture of a medicament for the prophylaxis and treatment of mitochondrial dysfunction selected from the group containing heart failure, non-alcoholic hepatitis, chronic fatigue, chronic fatigue syndrome, or fibromyalgia.

4. The use according to any of claims 1 to 3, wherein the molar ratio of magnesium orotate to folic acid is 2-25:1, in particular 20:1.

5. The use according to any of claims 1 to 4, wherein the agent additionally contains at least one or more substances selected from the group containing zinc orotate, benfotiamine, vitamin D and vitamin B.

6. The use according to any of claims 1 to 4, wherein the agent additionally contains at least one or more substances selected from the group containing zinc orotate, vitamin D3, thiamine, vitamin B6, vitamin B12 and benfotiamine.

7. The use according to any of the preceding claims, wherein the agent is a drug or a dietary supplement or a balanced diet.

8. Pharmaceutical preparations containing an agent for use according to any of claims 1 to 7, optionally together with suitable carrier substances, in particular in the form of drops, juice, syrup, tablets, sugar-coated tablets, capsules, sustained-release formulations, infusions, ointments, emulsions, or powder.

9. Pharmaceutical preparations containing an agent for use according to any of claims 1 to 7 together with excipients and additives.